Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning Blog Post
Publication: Clinical and Translational Science Abstract Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully representative in age, gender, ethnicity, medical status, or socioeconomic...
QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments Blog Post
Discover how Certara uses QSP modeling to advance the development of KK2269, a bispecific antibody targeting CD40 and EpCAM. This innovative approach optimized combination therapies, predicted pharmacokinetics, and enhanced cancer treatment efficacy.
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara Blog Post
[event_date_range]
A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3 Blog Post
Explore a cutting-edge minimal PBPK/PD oncology mouse model for 212Pb-based Radio-DARPin MP0712, meticulously designed to analyze and optimize tumor-targeting efficacy for DLL3 in small cell lung cancer.
How a budget-impact analysis complements cost-effectiveness to present a balanced economic outlook Blog Post
Kinga Pacocha Noemi Hummel June 16, 2025 Editor’s note: This is the third of four articles in our series on the crucial role health economic modeling plays in evaluating the... Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power Blog Post
June 16, 2025 RADNOR, PA – June 16, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.6. Phoenix...
Certara Earns Great Place to Work Certification™ for Fourth Consecutive Year Blog Post
Certara wins Great Place to Work Certification, with 85% of employees praising workplace culture, innovation, and collaboration.
